For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
9
views
9
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      322
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Baricitinib is an oral selective Janus kinase 1/2 inhibitor that has achieved clinically meaningful outcomes for scalp, eyebrow, and eyelash hair regrowth in patients with severe alopecia areata (AA) at week 36 of treatment. Treatment with baricitinib, 4 mg, has resulted in higher response rates than baricitinib, 2 mg, at weeks 36 and 52.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Alopecia areata

          C. Herbert Pratt, Lloyd E. King, Andrew G. Messenger … (2017)
          Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. Skin biopsies of affected skin show a lymphocytic infiltrate in and around the bulb or the lower part of the hair follicle in the anagen (hair growth) phase. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata. Genetic studies in patients and mouse models have shown that alopecia areata is a complex, polygenic disease. Several genetic susceptibility loci were identified to be associated with signalling pathways that are important to hair follicle cycling and development. Alopecia areata is usually diagnosed based on clinical manifestations, but dermoscopy and histopathology can be helpful. Alopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the near future.
          Article 0 comments Cited 204 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Two Phase 3 Trials of Baricitinib for Alopecia Areata

            Brett King, Manabu Ohyama, Ohsang Kwon … (2022)
            Article 0 comments Cited 97 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review

              Brett King, Brittany G. Craiglow, Lucy Y Liu (2016)
              Alopecia areata (AA) is a common skin disease that is frequently emotionally devastating. Several studies have examined the effect of AA on health-related quality of life (HRQoL). We performed a systematic review of all published studies of HRQoL in patients with AA. Eleven studies met inclusion criteria, incorporating data from 1986 patients. Patients with AA consistently demonstrate poor HRQoL scores, with greater extent of scalp involvement associated with lower HRQoL. HRQoL experienced by patients with AA is similar to that seen in patients with other chronic skin diseases including atopic dermatitis and psoriasis.
              Article 0 comments Cited 59 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): JAMA Dermatol
                Title: JAMA dermatology
                Publisher: American Medical Association (AMA)
                ISSN (Electronic): 2168-6084
                ISSN (Print): 2168-6068
                Publication date (Electronic): Sep 01 2023
                Volume: 159
                Issue: 9
                Affiliations
                [1 ] Department of Dermatology, Stanford University School of Medicine, Stanford, California.
                [2 ] Department of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham.
                [3 ] Departments of Dermatology and Histopathology, Cleveland Clinic Foundation, Cleveland, Ohio.
                [4 ] Eli Lilly and Company, Indianapolis, Indiana.
                [5 ] Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
                Article
                Publisher Item ID: 2808309
                DOI: 10.1001/jamadermatol.2023.2581
                PMC ID: 10413213
                PubMed ID: 37556146
                SO-VID: 05137aeb-9b71-4210-a4fc-b74d2b3bb30a
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content322

                See all similar

                Cited by1

                See all cited by

                Most referenced authors74

                See all reference authors